BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.comhttp://www.bioagilytix.com/
BioAgilytix earns FDA Breakthrough Device Designation for an anti-AAV antibody assay advancing gene therapy for rare disease.
New LC/MS investments across three continents enhance BioAgilytix’s ability to support complex, regulated biopharma programs globally.
annualmeeting.asgct.org